store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Opnurasib (JDQ-443) 是一种可口服且具有选择性和有效性的共价 KRAS G12C 抑制剂,具有抗肿瘤活性,可用于研究晚期非小细胞肺癌。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,250 | 现货 | ||
5 mg | ¥ 3,150 | 现货 | ||
10 mg | ¥ 4,590 | 现货 | ||
25 mg | ¥ 7,280 | 现货 | ||
50 mg | 特惠询价 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,630 | 现货 |
产品描述 | Opnurasib (JDQ-443) is an orally available and selective and potent covalent KRAS G12C inhibitor with antitumor activity for the study of advanced non-small cell lung cancer. |
体外活性 |
Opnurasib selectively forms a covalent bond with and inhibits GDP-bound KRASG12C, demonstrating a low reversible binding affinity to the RAS switch II pocket. Additionally, it effectively hinders the proliferation of cell lines carrying KRASG12C mutations, as well as those with double mutations G12C/H95, G12C/R68S, and G12C/Y96.[2] Opnurasib induces dose-dependent decreases in phosphorylated ERK (pERK) levels and inhibits the proliferation of KRASG12C-mutated cell lines NCI-H358 and NCI-H2122, exhibiting IC50 values of 0.018 and 0.063 μM, respectively.[2] |
体内活性 | Opnurasib elicits distinct antitumor responses in patient-derived xenograft (PDX) models of non-small cell lung cancer (NSCLC) and colorectal tumors, and these responses are further enhanced when Opnurasib is used in combination with other therapeutic agents.[2] |
别名 | NVP-JDQ443, JDQ-443, Opnurasib |
分子量 | 526.03 |
分子式 | C29H28ClN7O |
CAS No. | 2653994-08-0 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 70 mg/mL (133.07 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.901 mL | 9.5052 mL | 19.0103 mL | 47.5258 mL |
5 mM | 0.3802 mL | 1.901 mL | 3.8021 mL | 9.5052 mL | |
10 mM | 0.1901 mL | 0.9505 mL | 1.901 mL | 4.7526 mL | |
20 mM | 0.0951 mL | 0.4753 mL | 0.9505 mL | 2.3763 mL | |
50 mM | 0.038 mL | 0.1901 mL | 0.3802 mL | 0.9505 mL | |
100 mM | 0.019 mL | 0.0951 mL | 0.1901 mL | 0.4753 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Opnurasib 2653994-08-0 GPCR/G Protein MAPK Ras JDQ 443 NVP-JDQ443 JDQ-443 NVP-JDQ-443 NVP-JDQ 443 JDQ443 Inhibitor inhibitor inhibit